About MEDICAMEN ORGANICS Limited

Medicamen Organic Limited was established in year 1995 and having more than 30 years of experience in pharmaceutical manufacturing. They are engaged in manufacturing of pharmaceutical dosage form such as Tablets, Capsules, Oral Liquids, and Ointments. They are having two WHO-GMP Certified Plant in Haridwar. The company is associated with many domestic and international companies such as Morepen, Anglo French, Elder, Bestochem, Shreya Lifesciences, Wipro, Win Medicare, Jagsonpal, Klitch Drugs, Tablet India Limited, Mission Pharma, SH Pharmaceuticals, Knoll, Healing, May & Baker, Emami and many more for manufacturing of their goods on contract basis and on Loan License basis. Their company is also engaged in exporting to African, CIS and SARRC countries and are registered in 13 countries. Their Plant 1 is meant for Iron tablets, and it is WHO GMP approved. Plant 2 is having facility non-Beta lactam Tablets, Capsules and Oral Liquids and ointments, it is also WHO GMP Approved

The product portfolio of Medicamen, consists of 84 products and comprises of wide range of drugs like, Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Proton Pump Inhibitor, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral and Nonsteroidal anti-inflammatory drug (NSAIDS).

INDIAN PHARMACEUTICAL INDUSTRY

According to a recent EY FICCI report, there has been growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US$ 130 billion in value by the end of 2030. Meanwhile, the global market size of pharmaceutical products is estimated to cross over the US$ 1 trillion mark in 2024.

India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving into a thriving industry growing at a CAGR of 9.43% in the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most pharmaceutical manufacturing facilities that comply with the US Food and Drug Administration (USFDA) and has 500 API producers that makeup around 8% of the worldwide API market.
Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a 97 large pool of scientists and engineers with the potential to steer industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the "pharmacy of the world" due to the low cost and high quality of its medicines. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The Pharma sector currently contributes to around 1.72% of the country’s GDP.

The market size of India's pharmaceuticals industry is expected to reach US$ 65 billion by 2024, and ~US$ 130 billion by 2030. According to government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India. India is among the top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in the Asia Pacific. In 2022, India’s Biotechnology industry crossed US$ 80.12 billion, growing 14% from the previous year.

During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. The domestic pharmaceutical industry would likely reach US$ 57 billion by FY25 and see an increase in operating margins of 100-150 basis points (bps). The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation.

In the global pharmaceuticals sector, India is a significant and rising player. India is the world's largest supplier of generic medications, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand. The Indian pharmaceutical sector is worth US$ 42 billion worldwide. In August 2021, the Indian pharmaceutical market increased by 17.7% annually, up from 13.7% in July 2020.

MEDICAMEN ORGANICS LIMITED STRENGTHS

1. Experienced Promoter and Management Team
2. Wide range of Products
3. Scalable Business Model
4. Quality assurance

MEDICAMEN ORGANICS LIMITED STRATEGIES

1. Improve global presence
2. Maintaining edge over competitors
3. Expansion Plan
4. Customer Satisfaction

MEDICAMEN ORGANICS LIMITED RISK FACTORS & CONCERNS

1. The products that they commercialize may not perform as expected.
2. If they inadvertently infringe on the patents of others, their business may be adversely affected.
3. Their global operations expose them to numerous and sometimes conflicting legal and regulatory requirements.
4. They are subject to risks associated with expansion into new markets.
5.The business activities are exposed to fluctuations in the prices of raw materials.